Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma

Autor: Mutis, T, Korst, CLBM, Bruins, WSC, Cosovic, Meliha, Verkleij, CPM, Twickler, Inoka, Le Clerre, Diane, Chion-Sotinel, Isabelle, Zweegman, S, Galetto, Roman, van de Donk, NWCJ

Publikováno v: Mutis, T, Korst, CLBM, Bruins, WSC, Cosovic, M, Verkleij, CPM, Twickler, I, Le Clerre, D, Chion-Sotinel, I, Zweegman, S, Galetto, R & van de Donk, NWCJ 2022, ' Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma ', Blood .
Blood. American Society of Hematology

Introduction: The substantial activity of chimeric antigen receptor (CAR) T-cells in multiple myeloma (MM) has recently been shown by the success of BCMA-CAR T-cell therapy. Nevertheless the difficulties in (timely) generation of CART cells for each

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cac1ec54545292812e44a1b34c878c7
https://research.vumc.nl/en/publications/41e92fe5-a553-4175-85d5-74bfe152c6bd

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Autor: Vera de Jonge, A., Duetz, C, Bruins, WSC, van Werkhoven, Erik, Nijland, M., van der Poel, Marjolein W. M., de Heer, K, Klerk, CPW, Sandberg, Yorick, Fijnheer, Rob, Mutsaers, Pim G.N.J., Issa, DE, Lara H Bohmer, van Kampen, Roel J.W., Visser, O, de Jong, D, Zijlstra-Baalbergen, JM, Mutis, T, Chamuleau, MED

Publikováno v: Blood. American Society of Hematology
Vera de Jonge, A, Duetz, C, Bruins, WSC, van Werkhoven, E, Nijland, M, van der Poel, M W M, de Heer, K, Klerk, CPW, Sandberg, Y, Fijnheer, R, Mutsaers, P G N J, Issa, DE, Lara H Bohmer, van Kampen, R J W, Visser, O, de Jong, D, Zijlstra-Baalbergen, JM, Mutis, T & Chamuleau, MED 202, ' Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion ', Blood .

Introduction Treatment of patients with high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) with intensified immune-chemotherapy DA-EPOCH-R results in a 48-month event-free survival of 71.0% [Dunleavy, Lancet Haematol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a0991eaec201425d3c465a738feb028
https://research.vumc.nl/en/publications/e9fcd0d7-06d9-43bd-b7cf-1caa86c2eb2c

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

Autor: De Jonge AV; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Bruins WSC; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Duetz C; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Korst CLBM; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Rentenaar R; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Cosovic M; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Eken M; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Kersten MJ; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Sandberg Y; Department of Internal Medicine, Maasstad Hospital, Rotterdam., Van Rijn RS; Department of Internal Medicine, Medisch Centrum Leeuwarden, Leeuwarden., Fijnheer R; Department of Internal Medicine, Meander Medisch Centrum, Amersfoort., Mutsaers P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam., Vergote VKJ; Department of Hematology, University Hospitals Leuven, Leuven., Issa D; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch., Beeker A; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp., Bilgin YM; Department of Internal Medicine, Adrz, Goes., Visser O; Department of Internal medicine, Isala, Zwolle., Van Werkhoven E; HOVON foundation, Rotterdam, The Netherlands; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam., Roemer MGM; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Chamuleau MED; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam., Mutis T; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam. t.mutis@amsterdamumc.nl.

Publikováno v: Haematologica [Haematologica] 2024 Nov 01; Vol. 109 (11), pp. 3760-3765. Date of Electronic Publication: 2024 Nov 01.

T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

Autor: Verkleij CPM; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., O'Neill CA; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Broekmans MEC; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Frerichs KA; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Bruins WSC; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Duetz C; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Kruyswijk S; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Baglio SR; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Skerget S; Janssen Research & Development, Spring House, Pennsylvania., Montes de Oca R; Janssen Research & Development, Spring House, Pennsylvania., Zweegman S; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Verona RI; Janssen Research & Development, Spring House, Pennsylvania., Mutis T; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., van de Donk NWCJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 15; Vol. 30 (14), pp. 3006-3022.

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

Autor: Verkleij CPM; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Frerichs KA; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Broekmans MEC; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Duetz C; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., O'Neill CA; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Bruins WSC; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Homan-Weert PM; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Minnema MC; University Medical Center Utrecht, Department of Hematology, Utrecht University, The Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Broijl A; Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands., Bos GMJ; Department of Hematology, Maastricht University Medical Center, The Netherlands., Kersten MJ; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.; Amsterdam UMC Location University of Amsterdam, Department of Hematology, Amsterdam, The Netherlands., Klein SK; Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands.; Department of Hematology, University Medical Center Groningen, The Netherlands., Shikhagaie MM; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Casneuf T; Janssen Research and Development, Beerse, Belgium., Abraham Y; Janssen Research and Development, Beerse, Belgium., Smets T; Janssen Research and Development, Beerse, Belgium., Vanhoof G; Janssen Research and Development, Beerse, Belgium., Cortes-Selva D; Janssen Research and Development, Spring House, PA, USA., van Steenbergen L; BioLizard, Ghent, Belgium., Ramos E; BioLizard, Ghent, Belgium., Verona RI; Janssen Research and Development, Spring House, PA, USA., Krevvata M; Janssen Research and Development, Spring House, PA, USA., Sonneveld P; Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands., Zweegman S; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Mutis T; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., van de Donk NWCJ; Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.

Publikováno v: HemaSphere [Hemasphere] 2023 May 02; Vol. 7 (5), pp. e881. Date of Electronic Publication: 2023 May 02 (Print Publication: 2023).